Ipca Laboratories Limited – NSE:IPCALAB.NS

Ipca Laboratories Limited stock price today

INR 2,159.6
+526.94
+32.28%
Financial Health
0
1
2
3
4
5
6
7
8
9

Ipca Laboratories Limited stock price monthly change

+33.44%
month

Ipca Laboratories Limited stock price quarterly change

+33.44%
quarter

Ipca Laboratories Limited stock price yearly change

+54.16%
year

Ipca Laboratories Limited key metrics

Market Cap
 402.32B
Enterprise value
 423.67B
P/E
 62.61
EV/Sales
 4.96
EV/EBITDA
 28.50
Price/Sales
 4.85
Price/Book
 6.17
PEG ratio
 0.36
EPS
 21.58
Revenue
 77.07B
EBITDA
 12.62B
Income
 5.47B
Revenue Q/Q
 34.49%
Revenue Y/Y
 23.43%
Profit margin
 7.75%
Oper. margin
 15.39%
Gross margin
 53.88%
EBIT margin
 15.39%
EBITDA margin
 16.38%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Ipca Laboratories Limited stock price history

Ipca Laboratories Limited stock forecast

Ipca Laboratories Limited financial statements

Profit Margin

Ipca Laboratories Limited (NSE:IPCALAB.NS): Profit margin
Jun 2023 15.87B 1.62B 10.26%
Sep 2023 20.33B 1.45B 7.13%
Dec 2023 20.52B 1.79B 8.76%
Mar 2024 20.33B 595.9M 2.93%
IPCALAB.NS income statement history

Ipca Laboratories Limited Financials Estimate

Ipca Laboratories Limited (NSE:IPCALAB.NS): Analyst Estimates
2026 103.81B 11.79B 11.36%
2027 116.11B 14.28B 12.3%

  • Analysts Price target

  • Financials & Ratios estimates

Show more

Quarterly Earnings

Ipca Laboratories Limited (NSE:IPCALAB.NS): Earnings per share (EPS)
2024-08-13 5 7.58
2024-12-18 0.1074 0.108
IPCALAB.NS earnings history
0.24%
Yield TTM
Ipca Laboratories Limited (NSE:IPCALAB.NS): Payout ratio
Payout ratio 0%
Ipca Laboratories Limited (NSE:IPCALAB.NS): Dividend Yield
2016 0.21%
2017 0%
2019 0.13%
2020 0.69%
2022 0.38%
IPCALAB.NS dividends history

Debt to Assets

Ipca Laboratories Limited (NSE:IPCALAB.NS): Debt to assets
Jun 2023 0 0
Sep 2023 113838000000 38.22B 33.58%
Dec 2023 0 0
Mar 2024 111012800000 33.74B 30.4%
IPCALAB.NS balance sheet history

Cash Flow

Ipca Laboratories Limited (NSE:IPCALAB.NS): Cash Flow
Mar 2023 1.39B 0 0
Jun 2023 1.38B 0 0
Sep 2023 1.80B 0 0
Dec 2023 1.99B 0 0
IPCALAB.NS cash flow history

Ipca Laboratories Limited alternative data

Ipca Laboratories Limited
Employees

Ipca Laboratories Limited (NSE:IPCALAB.NS): Employee count
Aug 2023 16,167
Sep 2023 16,167
Oct 2023 16,167
Nov 2023 16,167
Dec 2023 16,167
Jan 2024 16,167
Feb 2024 16,167
Apr 2024 16,167
May 2024 16,167
Jun 2024 16,167
Jul 2024 16,167

Ipca Laboratories Limited other data

Ipca Laboratories Limited
Executives

Insider Compensation
Mr. Premchand Godha A.C. A., B. Com., CA (1946) Chairman, Chief Executive Officer & MD
 $107,920,000
Mr. Ajit Kumar Bhanwarlal Jain (1955) Chief Financial Officer, Joint MD & Executive Director
 $64,460,000
Mr. Pranay Godha (1972) Executive Director
 $32,410,000
Mr. Prashant P. Godha (1975) Executive Director
 $30,400,000

Frequently Asked Questions (FAQ)

  • What's the price of Ipca Laboratories Limited stock today?

    One share of Ipca Laboratories Limited stock can currently be purchased for approximately $2,159.6.

  • When is Ipca Laboratories Limited's next earnings date?

    Ipca Laboratories Limited is estimated to report earnings on Monday, 11 Aug 2025.

  • Does Ipca Laboratories Limited pay dividends?

    Yes, Ipca Laboratories Limited pays dividends and its trailing 12-month yield is 0.25% with 0% payout ratio. The last Ipca Laboratories Limited stock dividend of $0 was paid on 12 Sep 2025.

  • How much money does Ipca Laboratories Limited make?

    Ipca Laboratories Limited has a market capitalization of 402.32B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 32.19% to 76.22B US dollars. Ipca Laboratories Limited earned 5.47B US dollars in net income (profit) last year or $0.11 on an earnings per share basis.

  • What is Ipca Laboratories Limited's stock symbol?

    Ipca Laboratories Limited is traded on the NSE under the ticker symbol "IPCALAB.NS".

  • What is Ipca Laboratories Limited's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.

  • How do i buy shares of Ipca Laboratories Limited?

    Shares of Ipca Laboratories Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Ipca Laboratories Limited's key executives?

    Ipca Laboratories Limited's management team includes the following people:

    • Mr. Premchand Godha A.C. A., B. Com., CA Chairman, Chief Executive Officer & MD(age: 79, pay: $107,920,000)
    • Mr. Ajit Kumar Bhanwarlal Jain Chief Financial Officer, Joint MD & Executive Director(age: 70, pay: $64,460,000)
    • Mr. Pranay Godha Executive Director(age: 53, pay: $32,410,000)
    • Mr. Prashant P. Godha Executive Director(age: 50, pay: $30,400,000)

  • How many employees does Ipca Laboratories Limited have?

    As Jul 2024, Ipca Laboratories Limited employs 16,167 workers.

  • When Ipca Laboratories Limited went public?

    Ipca Laboratories Limited is publicly traded company for more then 29 years since IPO on 1 Jan 1996.

  • What is Ipca Laboratories Limited's official website?

    The official website for Ipca Laboratories Limited is ipca.com.

  • How can i contact Ipca Laboratories Limited?

    Ipca Laboratories Limited can be reached via phone at +91 22 6210 5000.

Ipca Laboratories Limited company profile:

Ipca Laboratories Limited

ipca.com
Exchange:

NSE

Full time employees:

17,335

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

+91 22 6210 5000
125, Kandivli Industrial Estate
Mumbai, 400067

:
ISIN: INE571A01038
CUSIP: Y4175R146